HighTide Therapeutics, Inc. (HIGHTIDE-B) reported no changes in its share structure for the month ended 31 July 2026, according to the company’s monthly return filed with the Hong Kong Stock Exchange on 3 August 2026.
The authorised share capital remained at 1.00 billion ordinary shares with a par value of USD 0.0001, equivalent to USD 0.10 million in total authorised capital.
Issued share capital was unchanged at 571.33 million ordinary shares, and the company continued to hold zero treasury shares. Consequently, total outstanding shares stayed at 571.33 million.
Management confirmed that the public float exceeded the Main Board’s 25 percent minimum threshold as of the month-end.
The filing recorded no activity under share options, warrants, convertibles, or other equity-linked instruments during the period.